{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T20:07:57Z","timestamp":1767902877082,"version":"3.49.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1007\/s11912-002-0066-3","type":"journal-article","created":{"date-parts":[[2007,6,1]],"date-time":"2007-06-01T15:19:20Z","timestamp":1180711160000},"page":"515-519","source":"Crossref","is-referenced-by-count":67,"title":["Management of angiosarcoma"],"prefix":"10.1007","volume":"4","author":[{"given":"G. Thomas","family":"Budd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"66_CR1","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO;2-6","volume":"59","author":"CA Holden","year":"1987","unstructured":"Holden CA, Spittle MF, Jones EW: Angiosarcoma of the face and scalp, prognosis and treatment. Cancer 1987, 59:1046\u20131057.","journal-title":"Cancer"},{"key":"66_CR2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/1097-0142(19950715)76:2<319::AID-CNCR2820760224>3.0.CO;2-8","volume":"76","author":"WH Morrison","year":"1995","unstructured":"Morrison WH, Byers RM, Garden AS, et al.: Cutaneous angiosarcoma of the head and neck: a therapeutic dilemma. Cancer 1995, 76:319\u2013327.","journal-title":"Cancer"},{"key":"66_CR3","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/S0360-3016(01)02753-5","volume":"52","author":"R Sasaki","year":"2002","unstructured":"Sasaki R, Soejima T, Kishi K, et al.: Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys 2002, 52:1032\u20131040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"66_CR4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/1097-0142(194805)1:1<64::AID-CNCR2820010105>3.0.CO;2-W","volume":"1","author":"FW Stewart","year":"1948","unstructured":"Stewart FW, Treves N: Lymphangiosarcoma in postmastectomy lymphedema. Cancer 1948, 1:64\u201381. This is the classic report of lymphangiosarcoma in postmastectomy lymphedema, a clinical scenario now termed the Stewart-Treves syndrome.","journal-title":"Cancer"},{"key":"66_CR5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/canjclin.31.5.284","volume":"31","author":"FW Stewart","year":"1981","unstructured":"Stewart FW, Treves N: Classics in oncology: lymphangiosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin 1981, 31:284\u2013299.","journal-title":"CA Cancer J Clin"},{"key":"66_CR6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/(SICI)1096-9098(200003)73:3<182::AID-JSO14>3.0.CO;2-N","volume":"73","author":"SR Grobmyer","year":"2000","unstructured":"Grobmyer SR, Daly JM, Glotzbach RE, Grobmyer AJ III: Role of surgery in the management of postmastectomy extremity angiosarcoma (Stewart-Treves syndrome). J Surg Oncol 2000, 73:182\u2013188.","journal-title":"J Surg Oncol"},{"key":"66_CR7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/00000372-198610000-00002","volume":"8","author":"E Alessi","year":"1986","unstructured":"Alessi E, Sala F, Berti E: Angiosarcomas in lymphedematous limbs. Am J Dermatopathol 1986, 8:371\u2013378.","journal-title":"Am J Dermatopathol"},{"key":"66_CR8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0360-3016(98)00537-9","volume":"44","author":"C Marchal","year":"1999","unstructured":"Marchal C, Weber B, de Lafontan B, et al.: Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive cancer centers. Int J Radiat Oncol Biol Phys 1999, 44:113\u2013119. This report describes the French experience with angiosarcoma occurring after breast-conserving therapy.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"66_CR9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<8::AID-CNCR3>3.0.CO;2-W","volume":"82","author":"WG Cahan","year":"1998","unstructured":"Cahan WG, Woodard HQ, Higinbotham NL, et al.: Sarcoma arising in irradiated bone: report of eleven cases. Cancer 1998, 82:8\u201334.","journal-title":"Cancer"},{"key":"66_CR10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0360-3016(01)02799-7","volume":"52","author":"J Yap","year":"2002","unstructured":"Yap J, Chuba PJ, Thomas R, et al.: Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys 2002, 52:1231\u20131237. This study reports the US experience with angiosarcoma arising after breast-conserving therapy.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"66_CR11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1046\/j.1365-2168.2000.01564.x","volume":"87","author":"JL Poggio","year":"2000","unstructured":"Poggio JL, Nagorney DM, Nascimento AG, et al.: Surgical treatment of adult primary hepatic sarcoma. Br J Surg 2000, 87:1500\u20131505.","journal-title":"Br J Surg"},{"key":"66_CR12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/1097-0142(19890715)64:2<484::AID-CNCR2820640223>3.0.CO;2-T","volume":"64","author":"M Shiraki","year":"1989","unstructured":"Shiraki M, Enterline HT, Brooks JJ, et al.: Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1989, 64:484\u2013490.","journal-title":"Cancer"},{"key":"66_CR13","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1200\/JCO.1987.5.6.840","volume":"5","author":"EC Borden","year":"1987","unstructured":"Borden EC, Amato DA, Rosenbaum C, et al.: Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987, 5:840\u2013850.","journal-title":"J Clin Oncol"},{"key":"66_CR14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1993.11.7.1269","volume":"11","author":"JH Edmonson","year":"1993","unstructured":"Edmonson JH, Ryan LM, Blum RH, et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993, 11:1269\u20131275.","journal-title":"J Clin Oncol"},{"key":"66_CR15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.1987.5.6.851","volume":"5","author":"LH Baker","year":"1987","unstructured":"Baker LH, Frank J, Fine G, et al.: Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial: a phase III Southwest Oncology Group Study (7613). J Clin Oncol 1987, 5:851\u2013861.","journal-title":"J Clin Oncol"},{"key":"66_CR16","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1200\/JCO.1993.11.7.1276","volume":"11","author":"K Antman","year":"1993","unstructured":"Antman K, Crowley J, Balcerzak SP, et al.: An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993, 11:1276\u20131285.","journal-title":"J Clin Oncol"},{"key":"66_CR17","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2000.18.10.2081","volume":"18","author":"J Verweij","year":"2000","unstructured":"Verweij J, Lee SM, Ruka W, et al.: Randomized phase II study of docetaxel versus doxorubicin in first-and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2081\u20132086.","journal-title":"J Clin Oncol"},{"key":"66_CR18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1200\/JCO.1995.13.7.1537","volume":"13","author":"A Santoro","year":"1995","unstructured":"Santoro A, Tursz T, Mouridsen H, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13:1537\u20131545.","journal-title":"J Clin Oncol"},{"key":"66_CR19","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/1097-0142(19951201)76:11<2248::AID-CNCR2820761111>3.0.CO;2-Y","volume":"76","author":"SP Balcerzak","year":"1995","unstructured":"Balcerzak SP, Benedetti J, Weiss GR, Natale RB: A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a Southwest Oncology Group study. Cancer 1995, 76:2248\u20132252.","journal-title":"Cancer"},{"key":"66_CR20","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3109\/07357909809011697","volume":"16","author":"ES Casper","year":"1998","unstructured":"Casper ES, Waltzman RJ, Schwartz GK, et al.: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest 1998, 16:442\u2013446.","journal-title":"Cancer Invest"},{"key":"66_CR21","first-page":"186","volume":"1","author":"VG Gian","year":"1996","unstructured":"Gian VG, Johnson TJ, Marsh RW, et al.: A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J Exp Ther Oncol 1996, 1:186\u2013190.","journal-title":"J Exp Ther Oncol"},{"key":"66_CR22","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P","volume":"86","author":"F Fata","year":"1999","unstructured":"Fata F, O\u2019Reilly E, Ilson D, et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 1999, 86:2034\u20132037. This report is the initial observation from investigators at Memorial Sloan-Kettering Cancer Center of responses of angiosarcoma of the scalp or face to treatment with paclitaxel.","journal-title":"Cancer"},{"key":"66_CR23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/jir.1992.12.455","volume":"12","author":"EC Borden","year":"1992","unstructured":"Borden EC, Kim K, Ryan L, et al.: Phase II trials of interferonsalpha and -beta in advanced sarcomas. J Interferon Res 1992, 12:455\u2013458.","journal-title":"J Interferon Res"},{"key":"66_CR24","first-page":"300","volume":"10","author":"B Guillot","year":"2000","unstructured":"Guillot B, Raison-Peyron N, Acevedo M, et al.: Angiosarcoma of the scalp and face: failure of an interferon alpha treatment. Eur J Dermatol 2000, 10:300\u2013302.","journal-title":"Eur J Dermatol"},{"key":"66_CR25","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/archderm.135.9.1035","volume":"135","author":"K Spieth","year":"1999","unstructured":"Spieth K, Gille J, Kaufmann R: Therapeutic efficacy of interferon alfa-2a and 13-cis-retinoic acid in recurrent angiosarcoma of the head. Arch Dermatol 1999, 135:1035\u20131037.","journal-title":"Arch Dermatol"},{"key":"66_CR26","first-page":"1187","volume":"140","author":"A Jackel","year":"1999","unstructured":"Jackel A, Deichmann M, Waldmann V, et al.: Regression of metastatic angiosarcoma of the skin after systemic treatment with liposome-encapsulated doxorubicin and interferonalpha. Br J Dermatol 1999, 140:1187\u20131188.","journal-title":"Br J Dermatol"},{"key":"66_CR27","first-page":"3516","volume":"5","author":"J Tomlinson","year":"1999","unstructured":"Tomlinson J, Barsky SH, Nelson S, et al.: Different patterns of angiogenesis in sarcomas and carcinomas. Clin Cancer Res 1999, 5:3516\u20133522.","journal-title":"Clin Cancer Res"},{"key":"66_CR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000227427","volume":"52","author":"M Ohsawa","year":"1995","unstructured":"Ohsawa M, Tomita Y, Kuratsu S, et al.: Angiogenesis in malignant fibrous histiocytoma. Oncology 1995, 52:51\u201354.","journal-title":"Oncology"},{"key":"66_CR29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF02303764","volume":"5","author":"NC Saenz","year":"1998","unstructured":"Saenz NC, Heslin MJ, Adsay V, et al.: Neovascularity and clinical outcome in high-grade extremity soft tissue sarcomas. Ann Surg Oncol 1998, 5:48\u201353.","journal-title":"Ann Surg Oncol"},{"key":"66_CR30","first-page":"959","volume":"6","author":"S Kawauchi","year":"1999","unstructured":"Kawauchi S, Fukuda T, Tsuneyoshi M: Angiogenesis does not correlate with prognosis or expression of vascular endothelial growth factor in synovial sarcomas. Oncol Rep 1999, 6:959\u2013964.","journal-title":"Oncol Rep"},{"key":"66_CR31","first-page":"166","volume":"6","author":"HM Verheul","year":"2000","unstructured":"Verheul HM, Hoekman K, Lupu F, et al.: Platelet and coagulation activation with vascular endothelial growth factor generation in soft tissue sarcomas. Clin Cancer Res 2000, 6:166\u2013171.","journal-title":"Clin Cancer Res"},{"key":"66_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004320050319","volume":"125","author":"U Graeven","year":"1999","unstructured":"Graeven U, Andre N, Achilles E, et al.: Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma. J Cancer Res Clin Oncol 1999, 125:577\u2013581.","journal-title":"J Cancer Res Clin Oncol"},{"key":"66_CR33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004320050036","volume":"126","author":"C Kuhnen","year":"2000","unstructured":"Kuhnen C, Lehnhardt M, Tolnay E, et al.: Patterns of expression and secretion of vascular endothelial growth factor in malignant soft-tissue tumours. J Cancer Res Clin Oncol 2000, 126:219\u2013225.","journal-title":"J Cancer Res Clin Oncol"},{"key":"66_CR34","first-page":"554a","volume":"19","author":"M Meyers","year":"2000","unstructured":"Meyers M, Clasen C, Gebhardt B, et al.: Gene expression of VEGF in human sarcoma [abstract]. Proc ASCO 2000, 19:554a.","journal-title":"Proc ASCO"},{"key":"66_CR35","first-page":"859","volume":"73","author":"M Hashimoto","year":"1995","unstructured":"Hashimoto M, Ohsawa M, Ohnishi A, et al.: Expression of vascular endothelial growth factor and its receptor mRNA in angiosarcoma. Lab Invest 1995, 73:859\u2013863.","journal-title":"Lab Invest"},{"key":"66_CR36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0002-9440(10)65729-X","volume":"153","author":"C Zietz","year":"1998","unstructured":"Zietz C, Rossle M, Haas C, et al.: MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 1998, 153:1425\u20131433.","journal-title":"Am J Pathol"},{"key":"66_CR37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0190-9622(99)70422-6","volume":"41","author":"T Yamamoto","year":"1999","unstructured":"Yamamoto T, Umeda T, Yokozeki H, Nishioka K: Expression of basic fibroblast growth factor and its receptor in angiosarcoma. J Am Acad Dermatol 1999, 41:127\u2013129.","journal-title":"J Am Acad Dermatol"},{"key":"66_CR38","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/(SICI)1097-0215(19961127)68:5<596::AID-IJC7>3.0.CO;2-U","volume":"68","author":"T Kalebic","year":"1996","unstructured":"Kalebic T, Tsokos M, Helman LJ: Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int J Cancer 1996, 68:596\u2013599.","journal-title":"Int J Cancer"},{"key":"66_CR39","first-page":"5117","volume":"60","author":"RA Brekken","year":"2000","unstructured":"Brekken RA, Overholser JP, Stastny VA, et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR\/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res 2000, 60:5117\u20135124.","journal-title":"Cancer Res"},{"key":"66_CR40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0006-2952(00)00529-3","volume":"61","author":"S Liekens","year":"2001","unstructured":"Liekens S, De Clercq E, Neyts J: Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001, 61:253\u2013270.","journal-title":"Biochem Pharmacol"},{"key":"66_CR41","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199205283262203","volume":"326","author":"RA Ezekowitz","year":"1992","unstructured":"Ezekowitz RA, Mulliken JB, Folkman J: Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326:1456\u20131463.","journal-title":"N Engl J Med"},{"key":"66_CR42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R","volume":"22","author":"F Riedel","year":"2000","unstructured":"Riedel F, Gotte K, Bergler W, et al.: Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 2000, 22:183\u2013189.","journal-title":"Head Neck"},{"key":"66_CR43","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1096\/fj.00-0627fje","volume":"15","author":"P Salven","year":"2001","unstructured":"Salven P, Anttonen K, Repo H, et al.: Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. FASEB J 2001, 15:1318\u20131320.","journal-title":"FASEB J"},{"key":"66_CR44","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","volume":"343","author":"S Zeuzem","year":"2000","unstructured":"Zeuzem S, Feinman SV, Rasenack J, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666\u20131672.","journal-title":"N Engl J Med"},{"key":"66_CR45","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","volume":"343","author":"EJ Heathcote","year":"2000","unstructured":"Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673\u20131680.","journal-title":"N Engl J Med"},{"key":"66_CR46","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0190-9622(99)70080-0","volume":"40","author":"JL Arbiser","year":"1999","unstructured":"Arbiser JL, Panigrathy D, Klauber N, et al.: The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice. J Am Acad Dermatol 1999, 40:925\u2013929. This laboratory study describes a model tumor system and the activity of several antiangiogenic agents in the treatment of this model tumor.","journal-title":"J Am Acad Dermatol"},{"key":"66_CR47","first-page":"267","volume":"8","author":"BA Ruggeri","year":"2002","unstructured":"Ruggeri BA, Robinson C, Angeles T, et al.: The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 2002, 8:267\u2013274.","journal-title":"Clin Cancer Res"},{"key":"66_CR48","first-page":"2376","volume":"59","author":"S Liekens","year":"1999","unstructured":"Liekens S, Verbeken E, Vandeputte M, et al.: A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res 1999, 59:2376\u20132683.","journal-title":"Cancer Res"},{"key":"66_CR49","first-page":"99","volume":"59","author":"TA Fong","year":"1999","unstructured":"Fong TA, Shawver LK, Sun L, et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59:99\u2013106.","journal-title":"Cancer Res"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0066-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-002-0066-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-002-0066-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:28:50Z","timestamp":1559435330000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-002-0066-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s11912-002-0066-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}